| Natural innate and adaptive immunity to cancer MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth Annual review of immunology 29 (1), 235-271, 2011 | 2692 | 2011 |
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer MH Kershaw, JA Westwood, LL Parker, G Wang, Z Eshhar, ... Clinical cancer research 12 (20), 6106-6115, 2006 | 1501 | 2006 |
| Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells LB John, C Devaud, CPM Duong, CS Yong, PA Beavis, NM Haynes, ... Clinical cancer research 19 (20), 5636-5646, 2013 | 792 | 2013 |
| Activating and inhibitory receptors of natural killer cells HJ Pegram, DM Andrews, MJ Smyth, PK Darcy, MH Kershaw Immunology and cell biology 89 (2), 216-224, 2011 | 732 | 2011 |
| Gene-engineered T cells for cancer therapy MH Kershaw, JA Westwood, PK Darcy Nature Reviews Cancer 13 (8), 525-541, 2013 | 576 | 2013 |
| Cytokines in cancer immunity and immunotherapy MJ Smyth, E Cretney, MH Kershaw, Y Hayakawa Immunological reviews 202 (1), 275-293, 2004 | 520 | 2004 |
| Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, ... Molecular Therapy 21 (11), 2122-2129, 2013 | 504 | 2013 |
| Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking Y Xu, Y Zhan, AM Lew, SH Naik, MH Kershaw The Journal of Immunology 179 (11), 7577-7584, 2007 | 465 | 2007 |
| Trafficking of T cells into tumors CY Slaney, MH Kershaw, PK Darcy Cancer research 74 (24), 7168-7174, 2014 | 429 | 2014 |
| Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2 MH Kershaw, G Wang, JA Westwood, RK Pachynski, HL Tiffany, ... Human gene therapy 13 (16), 1971-1980, 2002 | 323 | 2002 |
| Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses PA Beavis, N Milenkovski, MA Henderson, LB John, B Allard, S Loi, ... Cancer immunology research 3 (5), 506-517, 2015 | 307 | 2015 |
| A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation MJ Ludford-Menting, J Oliaro, F Sacirbegovic, ETY Cheah, N Pedersen, ... Immunity 22 (6), 737-748, 2005 | 306 | 2005 |
| Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy PA Beavis, MA Henderson, L Giuffrida, JK Mills, K Sek, RS Cross, ... The Journal of clinical investigation 127 (3), 929-941, 2017 | 304 | 2017 |
| Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity AJ Davenport, RS Cross, KA Watson, Y Liao, W Shi, HM Prince, ... Proceedings of the National Academy of Sciences 115 (9), E2068-E2076, 2018 | 291 | 2018 |
| Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors NM Haynes, JA Trapani, MWL Teng, JT Jackson, L Cerruti, SM Jane, ... Blood, The Journal of the American Society of Hematology 100 (9), 3155-3163, 2002 | 244 | 2002 |
| CAR T‐cell therapy of solid tumors CSM Yong, V Dardalhon, C Devaud, N Taylor, PK Darcy, MH Kershaw Immunology and cell biology 95 (4), 356-363, 2017 | 224 | 2017 |
| Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy C Devaud, LB John, JA Westwood, PK Darcy, MH Kershaw Oncoimmunology 2 (8), e25961, 2013 | 224 | 2013 |
| Autoimmunity associated with immunotherapy of cancer SM Amos, CPM Duong, JA Westwood, DS Ritchie, RP Junghans, ... Blood, The Journal of the American Society of Hematology 118 (3), 499-509, 2011 | 220 | 2011 |
| Supernatural T cells: genetic modification of T cells for cancer therapy MH Kershaw, MWL Teng, MJ Smyth, PK Darcy Nature Reviews Immunology 5 (12), 928-940, 2005 | 215 | 2005 |
| CARs versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment CY Slaney, P Wang, PK Darcy, MH Kershaw Cancer Discovery 8 (8), 924-934, 2018 | 209 | 2018 |
